Combating Antimicrobial Resistance: Policy Recommendations to Save Lives
Year: 2011
Type: article
Abstract: An ''Antibiotic Innovation and Conservation (AIC) Fee'' should be established, 75% of which should be used
Source: Clinical Infectious Diseases
DOI: 10.1093/cid/cir153
Author: Infectious Diseases Society of America (IDSA)
Language: English
Subfield: Infectious Diseases
Field: Medicine
Domain: Health Sciences
Open Access status: green
Funders: Bill and Melinda Gates Foundation, Eli Lilly and Company, Pfizer, AstraZeneca, GlaxoSmithKline, Sanofi, Gilead Sciences, Viropharma, Infectious Diseases Society of America, Association of Public Health Laboratories, Medicines Company, Gojo Industries, Nabriva Therapeutics, Eisai, Astellas Pharma, National Institutes of Health, Centers for Disease Control and Prevention, Agency for Healthcare Research and Quality, Biomedical Advanced Research and Development Authority, National Institute of Allergy and Infectious Diseases
OpenAlex ID: W846546774